← Back to Search

Genomic Testing

Genomic Studies for Early Detection of Myeloid Leukemia or Bone Marrow Failure Syndrome

N/A
Recruiting
Led By Mrinal S Patnaik, MBBS
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with Marrow failure syndromes with myeloid malignancy predisposition- telomere dysfunction, chromosomal breakage disorders, etc.
Patients with Idiopathic cytopenias of unclear significance (ICUS)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 5 years
Awards & highlights

Study Summary

This trial uses genomic and functional studies to identify patients with early signs of myeloid neoplasms or inherited bone marrow failure syndromes.

Who is the study for?
This study is for individuals with early signs of myeloid cancers or inherited bone marrow failure syndromes. It includes those with clonal hematopoiesis, age-related changes in blood cells, unclear cytopenias, and low-risk Myelodysplastic Syndromes. People who can't understand or sign the consent form are excluded.Check my eligibility
What is being tested?
The trial is focused on monitoring patients using genomic studies to identify and diagnose precursor conditions to myeloid neoplasms and inherited bone marrow failures. There's no specific medication being tested; it's more about follow-up studies.See study design
What are the potential side effects?
Since this trial involves follow-ups rather than direct interventions like medications or treatments, there are no typical side effects associated with drugs. However, participants may experience discomfort from routine medical procedures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a bone marrow failure syndrome with a risk for blood cancer.
Select...
I have been diagnosed with ICUS.
Select...
I have a genetic condition that increases my cancer risk.
Select...
I have been diagnosed with CHIP.
Select...
I have been diagnosed with CCUS.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of subjects whose cytopenias are persistent or progressive over the course of the 5 year study
Secondary outcome measures
Number of subjects who have evolved to myelodspalstic syndrome (MDS) or acute myeloid leukemia (aml) over the course of the five year study

Trial Design

1Treatment groups
Experimental Treatment
Group I: Potential Premyeloid Cancer or Bone Marrow Failure PatientsExperimental Treatment1 Intervention
Follow up provided for patients tested using Next Generation Sequencing (NGS) and other relevant functional studies

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,190 Previous Clinical Trials
3,757,101 Total Patients Enrolled
Mrinal S Patnaik, MBBSPrincipal InvestigatorMayo Clinic

Media Library

Genomic Testing (Genomic Testing) Clinical Trial Eligibility Overview. Trial Name: NCT02958462 — N/A
Myeloid Leukemia Research Study Groups: Potential Premyeloid Cancer or Bone Marrow Failure Patients
Myeloid Leukemia Clinical Trial 2023: Genomic Testing Highlights & Side Effects. Trial Name: NCT02958462 — N/A
Genomic Testing (Genomic Testing) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02958462 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are volunteers still being accepted for this research experiment?

"According to the clinicaltrials.gov portal, this trial is currently enrolling suitable candidates after being initially posted on November 1st 2016 and amended most recently on June 28th 2022."

Answered by AI

What is the size of the cohort involved in this clinical experiment?

"Correct. Accordingly, clinicaltrials.gov reports that this investigation is actively recruiting participants since it was first uploaded on November 1st 2016 and updated most recently on June 28th 2022. The trial seeks to recruit 1300 individuals from one centre of research."

Answered by AI
~945 spots leftby Sep 2030